Over the last month, Phillip Frost has reported 14 Buy trades on OPK for a total of $15.09M. In addition to Phillip Frost, 4 other OPK executives reported Buy trades in the last month.
Based on Opko Health`s latest earnings report from June 30, the company posted quarterly revenue of $42.43M and GAAP net loss of $42.77M. In comparison, last year the company earned revenue of $23.55M and had a GAAP net loss of $25.48M. The company has a one year high of $19.20 and a one year low of $8.02. Currently, Opko Health has an average volume of 3.43M.
Six different firms, including Barrington and Cowen & Co., currently also have a Buy rating on the stock.
Looking at blogger coverage of OPK, there is a 84% Bullish tendency on the stock, in relation to a 75% average bullish tendency within the Healthcare sector.
Over the last 3 months, the insider sentiment on Opko Health has been positive based on 142 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.
Opko Health Inc is a biopharmaceutical and diagnostics company. The Company is engaged in the research and development of pharmaceutical products and vaccines.